How often you need to check a thyroid nodule depends on how suspicious it looks on ultrasound and whether it’s already been biopsied. Most nodules fall into a schedule ranging from every 6 months to every 2 years, and some low-risk nodules don’t need routine monitoring at all. After 5 years of stability, many people can stop surveillance entirely.
The Two Systems That Set Your Schedule
Two major frameworks guide thyroid nodule monitoring in the U.S., and your doctor likely uses one of them. The American Thyroid Association (ATA) guidelines sort nodules by their ultrasound appearance into categories like high suspicion, low to intermediate suspicion, and very low suspicion. The American College of Radiology uses a point-based scoring system called TI-RADS, which assigns each nodule a level from TR1 (benign) to TR5 (highly suspicious). Both systems arrive at similar conclusions: the more worrisome a nodule looks, the more frequently it needs imaging.
Nodules That Haven’t Been Biopsied
If your nodule was found incidentally or doesn’t meet the size threshold for a biopsy, the follow-up schedule is based purely on its ultrasound appearance.
Under the ATA guidelines, a nodule with high-suspicion features should be rechecked with ultrasound in 6 to 12 months. Nodules with low to intermediate suspicion get a repeat ultrasound at 12 to 24 months. Very low suspicion nodules, including spongiform types that look like a sponge with many small fluid-filled spaces, can wait at least 24 months. And if a very low suspicion nodule is 1 cm or smaller, or it’s a simple fluid-filled cyst, routine follow-up isn’t recommended at all.
The TI-RADS system is similar but adds specific long-term timelines. A TR5 (highly suspicious) nodule gets annual scans for up to 5 years. A TR4 (moderately suspicious) nodule gets checked at 1, 2, 3, and 5 years. A TR3 (mildly suspicious) nodule gets imaging at 1, 3, and 5 years. TR1 and TR2 nodules, which look clearly benign or not suspicious, don’t need follow-up imaging.
After a Benign Biopsy Result
A biopsy that comes back benign is reassuring, but it doesn’t end monitoring right away. The schedule shifts based on how the nodule looked on the ultrasound that prompted the biopsy in the first place.
If the nodule had high-suspicion features on ultrasound despite its benign biopsy, the ATA recommends a repeat ultrasound and possibly another biopsy within 12 months. Nodules with low to intermediate suspicion features get rechecked at 12 to 24 months. Very low suspicion nodules that were biopsied can wait at least 24 months before the next ultrasound, if one is done at all.
A commonly used approach from the American Association of Clinical Endocrinologists simplifies this: get an ultrasound about 12 months after a benign biopsy, and if nothing has changed, push the next one out to 24 months. Research from Brigham and Women’s Hospital found that most benign nodules can safely be followed every 2 to 4 years with no increased risk of harm.
What Counts as Growth
Your doctor is watching for meaningful growth between scans, but not every tiny change matters. The threshold that raises concern is a greater than 20% increase in at least two dimensions, with a minimum increase of 2 mm. A study comparing benign and malignant nodules found that nodules meeting this growth definition were about 2.5 times more likely to be cancerous. Interestingly, other common measures of growth, like gaining more than 2 mm per year or a 50% increase in volume, did not reliably distinguish cancerous nodules from benign ones.
If your nodule does show significant growth or develops new suspicious features on follow-up ultrasound, your doctor will typically recommend a biopsy or repeat biopsy regardless of where you are in the monitoring schedule. Under TI-RADS, if a nodule’s suspicion level increases on follow-up, the next scan should happen in 1 year no matter what the original timeline was.
When You Can Stop Monitoring
Five years of stability is the general benchmark for stepping back from surveillance. The ACR TI-RADS guidelines state that imaging can stop at 5 years if a nodule hasn’t changed in size, because stability over that span reliably indicates benign behavior.
In practice, many patients stop follow-up sooner. A study tracking patients at an endocrinology clinic found that 57% eventually dropped out of monitoring, most commonly because the nodule stayed the same size during the first 2 to 3 years. Among those who dropped out for this reason, 89% did so by the five-year mark. Older patients were more likely to discontinue follow-up. While dropping out isn’t the same as a doctor formally ending surveillance, the pattern reflects the low-risk reality of stable, biopsy-confirmed benign nodules.
Symptoms That Warrant an Earlier Check
If you develop new difficulty swallowing, a feeling of pressure in your neck, or hoarseness that doesn’t go away, those symptoms justify moving up your next ultrasound regardless of the scheduled timeline. These signs can indicate that the nodule is growing or pressing on nearby structures. Nodules causing voice or swallowing problems are sometimes treated with surgery even if biopsy results are benign, simply because of the mechanical effects on your throat.
How Monitoring Differs in Children
Children with thyroid nodules generally follow the same ultrasound-based monitoring approach as adults, but with a few important differences. Nodule size alone is less useful in kids because the thyroid changes as they grow, so doctors rely more heavily on ultrasound characteristics and clinical context when deciding what needs a biopsy. The ATA’s pediatric guidelines recommend that benign nodules in children be followed with serial ultrasounds and re-biopsied if suspicious features appear or the nodule keeps growing.
For children who have had thyroid cancer surgery, follow-up is more intensive. Low-risk patients get an ultrasound at 6 months after surgery and then annually for 5 years. Higher-risk children are scanned every 6 to 12 months for the first 5 years. Beyond that, the schedule is individualized based on how likely recurrence is.